- Home
- SOPH vs PWRL Comparison
SOPH vs PWRL Comparison
Compare SOPH & PWRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOPH | PWRL |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 475.2M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SOPH | PWRL |
|---|---|---|
| Price | $7.38 | $12.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 583.2K | 175.6K |
| Earning Date | 11-03-2026 | N/A |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.24 | N/A |
| Revenue Next Year | $24.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $9.41 |
| 52 Week High | $8.98 | $16.31 |
Technical Indicators
Market Signals| Indicator | SOPH | PWRL |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 55.42 |
| Support Level | $4.58 | $10.36 |
| Resistance Level | $8.80 | $12.57 |
| Average True Range (ATR) | 0.53 | 0.49 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 45.08 | 60.53 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About PWRL Powerlaw Corp. Common Stock
Powerlaw Corp is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation. It seeks to achieve its investment objective by investing in the equity and equity-linked securities of a concentrated portfolio of approximately 12 to 15 late-stage technology companies.